MAG and neuropathy: A study of 26 participants randomised to placebo vs. rituximab for anti-MAG (myelin-associated glycoprotein) neuropathy, a subtype of CIDP, demonstrated an increased rate of improvement in the neuropathy scores of four participants in the treatment group vs. none in the placebo group, which was found to be statistically significant [127].